Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
NEW YORK, July 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
http://www.reportlinker.com/p02166739/Viibryd-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.html
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
Summary
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014).
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Viibryd for the US from 2013 to 2023.
- Sales information covered for the US.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Viibryd performance
- Obtain sales forecast for Viibryd from 2013-2023 in the US.
1 Table of Contents
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Classification 13
3.3 Symptoms and Subtypes of Major Depressive Disorder 15
3.4 Prognosis 16
3.5 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Viibryd (Vilazodone) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 35
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed MDD Patients 37
7.4.2 Percent of Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 38
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in this Study 40
7.6 About the Authors 42
7.6.1 Analyst 42
7.6.2 Therapy Area Directors 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44
1.1
List of Tables
Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 14
Table 2: Subtypes of Major Depressive Disorder 15
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 17
Table 4: Treatment Guidelines for Major Depressive Disorder 19
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 21
Table 6: Leading Treatments for MDD, 2013 27
Table 7: Product Profile - Viibryd 29
Table 8: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 29
Table 9: Safety of Viibryd - Five Most Frequently Reported Adverse Events 30
Table 10: Viibryd SWOT Analysis, 2023 31
Table 11: Global MDD Sales Forecasts ($m) for Viibryd, 2013-2023 32
Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 41
1.2
List of Figures
Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 13
Figure 2: Disease Management Model for Major Depressive Disorder 23
Figure 3: Major Depressive Disorder Treatment Algorithm 25
Companies Mentioned
To order this report: Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
http://www.reportlinker.com/p02166739/Viibryd-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article